ETX-155
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ETX-155 is a GABA A receptor positive allosteric modulator and neurosteroid which is or was under development for the treatment of depressive disorders, seizures, and fibromyalgia. It is taken orally and has an elimination half-life of 24 to 40 hours. The drug produces antidepressant-like, anxiolytic-like, and anticonvulsant effects in rodents. Side effects of ETX-155 in humans include somnolence, fatigue, dizziness, and headache. ETX-155 was originated by Athenen Therapeutics and is or was under development by Climb Bio and/or Eliem Therapeutics. As of October 2024, development of the drug for all indications has been suspended or discontinued. It reached phase 1 clinical trials prior to the suspension or discontinuation of its development.
ETX-155 is a GABA A receptor positive allosteric modulator and neurosteroid which is or was under development for the treatment of depressive disorders, seizures, and fibromyalgia. It is taken orally and has an elimination half-life of 24 to 40 hours. The drug produces antidepressant-like, anxiolytic-like, and anticonvulsant effects in rodents. Side effects of ETX-155 in humans include somnolence, fatigue, dizziness, and headache. ETX-155 was originated by Athenen Therapeutics and is or was under development by Climb Bio and/or Eliem Therapeutics. As of October 2024, development of the drug for all indications has been suspended or discontinued. It reached phase 1 clinical trials prior to the suspension or discontinuation of its development.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372018964 under CC BY-SA 4.0; modifications have been made.